Pulse Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 8.54 Cr
as on 29-06-2024
- Paid Up Capital ₹ 7.94 Cr
as on 29-06-2024
- Company Age 27 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 118.34 Cr
as on 29-06-2024
- Satisfied Charges ₹ 6.00 Cr
as on 29-06-2024
- Revenue 7.30%
(FY 2023)
- Profit 19.52%
(FY 2023)
- Ebitda 3.76%
(FY 2023)
- Net Worth 21.67%
(FY 2023)
- Total Assets 38.08%
(FY 2023)
About Pulse Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 8.54 Cr and a paid-up capital of Rs 7.94 Cr.
The company currently has active open charges totaling ₹118.34 Cr. The company has closed loans amounting to ₹6.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Pulse Pharmaceuticals Private Limited India is Ramesh Surampudi as COMPANY SECRETARY. Venkat Katragadda, Suresh Katragadda, Srikanth Myneni, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24239TG1997PTC026151
- Company No.
026151
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jan 1997
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Pulse Pharmaceuticals Private Limited offer?
Pulse Pharmaceuticals Private Limited offers a wide range of products and services, including Antiparasitic Drug, Ivermectin Tablets, Paracetamol Tablets, Paracip Tablets.
Who are the key members and board of directors at Pulse Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramesh Surampudi  | Company Secretary | Current |
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rambhau Devraj | Director | 01-Jun-2015 | Current |
| Venkat Katragadda | Director | 09-Jan-1997 | Current |
| Suresh Katragadda | Director | 24-Feb-2004 | Current |
| Srikanth Myneni | Director | 01-Sep-2017 | Current |
| Venkateswarlu Nelabhotla | Director | 10-Nov-2022 | Current |
| Divya Katragadda | Director | 09-May-2019 | Current |
Financial Performance and Corporate Structure Insights of Pulse Pharmaceuticals.
Pulse Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.3% increase. The company also saw a substantial improvement in profitability, with a 19.52% increase in profit. The company's net worth Soared by an impressive increase of 21.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pulse Pharmaceuticals?
In 2023, Pulse Pharmaceuticals had a promoter holding of 70.59% and a public holding of 29.41%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vyome Biosciences Private LimitedActive 14 years 4 monthsVenkateswarlu Nelabhotla is a mutual person
Medzara Healthtech Private LimitedActive 5 years 7 monthsVenkateswarlu Nelabhotla is a mutual person
Pulse Nutri Science Private LimitedActive 14 years 7 monthsVenkat Katragadda and Suresh Katragadda are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Nov 2023 | ₹5.00 Cr | Open |
Others Creation Date: 31 Jul 2023 | ₹1.49 Cr | Open |
Others Creation Date: 28 May 2023 | ₹1.40 Cr | Open |
How Many Employees Work at Pulse Pharmaceuticals?
Pulse Pharmaceuticals has a workforce of 996 employees as of May 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pulse Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pulse Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
